Journal Article
. 2004 May; 96(10):739-49.
doi: 10.1093/jnci/djh131.

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

Mark D Pegram 1 Gottfried E Konecny  Carminda O'Callaghan  Malgorzata Beryt  Richard Pietras  Dennis J Slamon  
Affiliations
  • PMID: 15150302
  •     125 citations

Abstract

Background: Trastuzumab, a humanized anti-HER2 antibody, increases the clinical benefit of first-line chemotherapy in patients with metastatic breast cancers that overexpress HER2. We characterized interactions between trastuzumab and chemotherapeutic agents commonly used in the treatment of breast cancer.

Methods: Multiple drug effect/combination index isobologram analysis was used to study the efficacy of chemotherapeutic drug plus trastuzumab combinations tested against four HER2-overexpressing breast cancer cell lines (SK-BR-3, BT-474, MDA-MB-361, and MDA-MB-453). Combination index values were derived from parameters of the median effect plots, and statistical tests were used to determine whether the mean combination index values at multiple effect levels were statistically significantly different from a combination index value of 1.0. Values less than 1.0 indicate synergistic interactions, values greater than 1.0 indicate antagonistic interactions, and values equal to 1.0 indicate additive interactions.

Results: At a wide range of clinically achievable drug concentrations, synergistic interactions were observed in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P =.010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]). Additive interactions were observed in all four cell lines with trastuzumab plus doxorubicin, epirubicin, and paclitaxel. Interactions between trastuzumab and gemcitabine were synergistic at low concentrations of gemcitabine and antagonistic at high concentrations. A synergistic interaction was observed with a three-drug combination of docetaxel plus carboplatin plus trastuzumab in SK-BR-3 cells (mean combination index value = 0.09; P<.001).

Conclusion: Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials.

Integrating trastuzumab in the treatment of breast cancer. Current status and future trends.
Alberto Ocaña, César A Rodríguez, Juan J Cruz.
Clin Transl Oncol, 2005 May 19; 7(3). PMID: 15899216
Review.
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
Christina H Yeon, Mark D Pegram.
Invest New Drugs, 2005 Sep 01; 23(5). PMID: 16133791
Review.
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
Jill E Kucab, Cathy Lee, +8 authors, Sandra E Dunn.
Breast Cancer Res, 2005 Sep 20; 7(5). PMID: 16168126    Free PMC article.
New paradigms for therapy for osteosarcoma.
Rajaram Nagarajan, Denis Clohisy, Brenda Weigel.
Curr Oncol Rep, 2005 Oct 14; 7(6). PMID: 16221377
Review.
Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Keith T Flaherty, Marcia S Brose.
Curr Oncol Rep, 2006 Mar 02; 8(2). PMID: 16507217
Review.
Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer.
Greg L Plosker, Susan J Keam.
Drugs, 2006 Apr 07; 66(4). PMID: 16597163
Review.
HER2 expression as a potential marker for response to therapy targeted to the EGFR.
D R Emlet, R Schwartz, +3 authors, S E Shackney.
Br J Cancer, 2006 Apr 20; 94(8). PMID: 16622439    Free PMC article.
Paclitaxel-carboplatin combination chemotherapy in advanced breast cancer: accumulating evidence for synergy, efficacy, and safety.
G Pentheroudakis, E Razis, +2 authors, G Fountzilas.
Med Oncol, 2006 May 25; 23(2). PMID: 16720915
Review.
HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
D N Church, A Bahl, A Jones, C G A Price.
J Neurooncol, 2006 Jul 06; 79(3). PMID: 16821088
Trastuzumab and breast cancer: developments and current status.
Eriko Tokunaga, Eiji Oki, +5 authors, Yoshihiko Maehara.
Int J Clin Oncol, 2006 Jul 20; 11(3). PMID: 16850126
Review.
Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
Chantal Bernard-Marty, Fabienne Lebrun, Ahmad Awada, Martine J Piccart.
Drugs, 2006 Sep 08; 66(12). PMID: 16956305
Review.
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
A Chan, M Martin, +14 authors, Navelbine Herceptin Project.
Br J Cancer, 2006 Sep 14; 95(7). PMID: 16969343    Free PMC article.
Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.
David A Mankoff, Finbarr O'Sullivan, William E Barlow, Kenneth A Krohn.
Acad Radiol, 2007 Mar 21; 14(4). PMID: 17368207    Free PMC article.
Review.
Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
Ermelinda De Maio, Carmen Pacilio, +20 authors, Andrea de Matteis.
BMC Cancer, 2007 Mar 22; 7. PMID: 17374151    Free PMC article.
Oral vinorelbine: role in the management of metastatic breast cancer.
Matti S Aapro, Pierfranco Conte, Emilio Esteban González, Véronique Trillet-Lenoir.
Drugs, 2007 Mar 28; 67(5). PMID: 17385939
Review.
HER2-positive breast cancer: current and future treatment strategies.
Ryan H Engel, Virginia G Kaklamani.
Drugs, 2007 Jun 06; 67(9). PMID: 17547474
Review.
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
Rupert Bartsch, Andrea Rottenfusser, +8 authors, Guenther G Steger.
J Neurooncol, 2007 Jun 09; 85(3). PMID: 17557136
Adjuvant trastuzumab: progress, controversies, and the steps ahead.
A A Joy, J R Mackey.
Curr Oncol, 2007 Jun 20; 13(1). PMID: 17576436    Free PMC article.
The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.
Amy Lin, Hope S Rugo.
Curr Treat Options Oncol, 2007 Jul 31; 8(1). PMID: 17660958
Review.
EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
Michael F Press, Heinz-Josef Lenz.
Drugs, 2007 Sep 22; 67(14). PMID: 17883287
Review.
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography.
Gabriela Kramer-Marek, Dale O Kiesewetter, +3 authors, Jacek Capala.
Eur J Nucl Med Mol Imaging, 2007 Dec 25; 35(5). PMID: 18157531    Free PMC article.
Breast tumour angiogenesis.
Stephen B Fox, Daniele G Generali, Adrian L Harris.
Breast Cancer Res, 2008 Jan 15; 9(6). PMID: 18190723    Free PMC article.
Review.
HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization.
Shy Chyi Wuang, Koon Gee Neoh, +2 authors, Deborah E Leckband.
Biomaterials, 2008 Feb 22; 29(14). PMID: 18289668    Free PMC article.
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
G E Konecny, N Venkatesan, +9 authors, K C Podratz.
Br J Cancer, 2008 Mar 13; 98(6). PMID: 18334972    Free PMC article.
Trastuzumab induces gastrointestinal side effects in HER2-overexpressing breast cancer patients.
Noor Al-Dasooqi, Joanne M Bowen, +3 authors, Dorothy M Keefe.
Invest New Drugs, 2008 Jul 10; 27(2). PMID: 18612591
Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.
Filippo Montemurro, Stefania Redana, +6 authors, Massimo Aglietta.
BMC Cancer, 2008 Jul 26; 8. PMID: 18652678    Free PMC article.
Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy).
G Schilling, M Bruweleit, +8 authors, M de Wit.
Invest New Drugs, 2008 Aug 13; 27(2). PMID: 18696011
A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer.
Andre Mihaljevic, Peter Büchler, +9 authors, Michael Geissler.
BMC Surg, 2009 Jan 10; 9. PMID: 19133157    Free PMC article.
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.
Y H Park, M J Park, +11 authors, Y-H Im.
Br J Cancer, 2009 Feb 26; 100(6). PMID: 19240719    Free PMC article.
Shock the heat shock network.
Cigdem Atay, Serkan Ugurlu, Nesrin Ozören.
J Clin Invest, 2009 Mar 24; 119(3). PMID: 19306500    Free PMC article.
Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.
Xianke Zeng, Deepali Sachdev, +2 authors, Douglas Yee.
Clin Cancer Res, 2009 Apr 09; 15(8). PMID: 19351773    Free PMC article.
Clinical trial designs for predictive biomarker validation: one size does not fit all.
Sumithra J Mandrekar, Daniel J Sargent.
J Biopharm Stat, 2009 Apr 23; 19(3). PMID: 19384694    Free PMC article.
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
S Dent, Sh Verma, +9 authors, K Pritchard.
Curr Oncol, 2009 Aug 13; 16(4). PMID: 19672422    Free PMC article.
Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.
Hye-Suk Han, Jin-Soo Kim, +9 authors, Yung-Jue Bang.
J Korean Med Sci, 2009 Oct 02; 24(5). PMID: 19794992    Free PMC article.
Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
Giulio Francia, Shan Man, +6 authors, Robert S Kerbel.
Clin Cancer Res, 2009 Oct 15; 15(20). PMID: 19825954    Free PMC article.
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
G E Konecny, R Glas, +10 authors, D J Slamon.
Br J Cancer, 2009 Oct 29; 101(10). PMID: 19861960    Free PMC article.
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.
J Lemieux, M Clemons, +9 authors, S Chia.
Curr Oncol, 2009 Oct 29; 16(5). PMID: 19862361    Free PMC article.
Molecular predictors of response to trastuzumab and lapatinib in breast cancer.
Francisco J Esteva, Dihua Yu, Mien-Chie Hung, Gabriel N Hortobagyi.
Nat Rev Clin Oncol, 2009 Dec 23; 7(2). PMID: 20027191
Review.
Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.
Jennifer B Jacob, Elena Quaglino, +6 authors, Wei-Zen Wei.
Cancer Res, 2010 Jan 06; 70(1). PMID: 20048073    Free PMC article.
Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Karly P Garnock-Jones, Gillian M Keating, Lesley J Scott.
Drugs, 2010 Jan 30; 70(2). PMID: 20108993
Review.
Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison.
Stefania Redana, Michela Donadio, +7 authors, Filippo Montemurro.
BMC Cancer, 2010 Feb 04; 10. PMID: 20122160    Free PMC article.
From bench to bedside: the growing use of translational research in cancer medicine.
Erin M Goldblatt, Wen-Hwa Lee.
Am J Transl Res, 2010 Feb 26; 2(1). PMID: 20182579    Free PMC article.
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
Norma O'Donovan, Annette T Byrne, +3 authors, John Crown.
Invest New Drugs, 2010 Mar 17; 29(5). PMID: 20229355
Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging.
Victor Chernomordik, Moinuddin Hassan, +3 authors, Jacek Capala.
Mol Imaging, 2010 Jul 21; 9(4). PMID: 20643022    Free PMC article.
Optimizing the management of HER2-positive early breast cancer: the clinical reality.
Su Verma, S Lavasani, +10 authors, D Rayson.
Curr Oncol, 2010 Aug 11; 17(4). PMID: 20697511    Free PMC article.
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
SaeGwang Park, Zhujun Jiang, +11 authors, Yang-Xin Fu.
Cancer Cell, 2010 Aug 17; 18(2). PMID: 20708157    Free PMC article.
Highly Cited.
The Role of Targeted Agents in the Treatment of Metastatic Breast Cancer.
Joachim Bischoff, Atanas Ignatov.
Breast Care (Basel), 2010 Sep 18; 5(3). PMID: 20847826    Free PMC article.
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer.
Anna Emde, Wolfgang J Köstler, Yosef Yarden, Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME).
Crit Rev Oncol Hematol, 2010 Oct 19; 84 Suppl 1. PMID: 20951604    Free PMC article.
Review.
Targeting HER2 in breast cancer: overview of long-term experience.
Evan Lantz, Ivan Cunningham, Gerald M Higa.
Int J Womens Health, 2010 Nov 13; 1. PMID: 21072285    Free PMC article.
[Principles and method of action of targeted therapies].
Christian F Singer.
Wien Med Wochenschr, 2010 Nov 17; 160(19-20). PMID: 21080269
Review.
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Gottfried E Konecny, Boris Winterhoff, +18 authors, Dennis J Slamon.
Clin Cancer Res, 2011 Feb 01; 17(6). PMID: 21278246    Free PMC article.
Highly Cited.
Immune therapy for breast cancer in 2010-hype or hope?
A Florescu, E Amir, N Bouganim, M Clemons.
Curr Oncol, 2011 Feb 19; 18(1). PMID: 21331271    Free PMC article.
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Devika Gajria, Sarat Chandarlapaty.
Expert Rev Anticancer Ther, 2011 Feb 24; 11(2). PMID: 21342044    Free PMC article.
Highly Cited. Review.
Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better.
Fausto Petrelli, Sandro Barni.
Med Oncol, 2011 Mar 15; 29(2). PMID: 21400217
Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.
Katherine H Rak Tkaczuk.
Breast Cancer (Auckl), 2011 Apr 16; 5. PMID: 21494397    Free PMC article.
Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.
T Waddell, A Kotsori, +9 authors, S Johnston.
Br J Cancer, 2011 Apr 28; 104(11). PMID: 21522147    Free PMC article.
Combining emerging agents in advanced breast cancer.
Thehang Luu, Cathie Chung, George Somlo.
Oncologist, 2011 May 06; 16(6). PMID: 21543509    Free PMC article.
Review.
Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes.
Yu Rim Lee, Seok Jae Huh, +9 authors, Hyuk-Chan Kwon.
J Breast Cancer, 2011 Aug 19; 14(2). PMID: 21847410    Free PMC article.
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
Soley Bayraktar, Ana M Gonzalez-Angulo, +7 authors, Funda Meric-Bernstam.
Cancer, 2011 Sep 29; 118(9). PMID: 21953213    Free PMC article.
Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab.
Parisa Yousefpour, Fatemeh Atyabi, +2 authors, Rassoul Dinarvand.
Int J Nanomedicine, 2011 Oct 07; 6. PMID: 21976974    Free PMC article.
Adjuvant trastuzumab in HER2-positive breast cancer.
Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group.
N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949    Free PMC article.
Highly Cited.
Recent developments in treatment stratification for metastatic breast cancer.
Sarah Barton, Charles Swanton.
Drugs, 2011 Nov 01; 71(16). PMID: 22035512
Review.
Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial.
Winston W Tan, Jacob B Allred, +7 authors, Edith A Perez.
Clin Breast Cancer, 2012 Mar 27; 12(2). PMID: 22444716    Free PMC article.
Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.
Leticia De Mattos-Arruda, Javier Cortes.
Oncologist, 2012 Apr 24; 17(5). PMID: 22523199    Free PMC article.
Review.
Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series.
Vincenzo Di Lauro, Elena Torrisi, +3 authors, Andrea Veronesi.
J Oncol, 2012 Apr 27; 2012. PMID: 22536237    Free PMC article.
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?
Harold J Burstein, Martine J Piccart-Gebhart, +6 authors, Clifford A Hudis.
J Clin Oncol, 2012 May 23; 30(18). PMID: 22614986    Free PMC article.
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.
Fabio Puglisi, Alessandro Marco Minisini, Carmine De Angelis, Grazia Arpino.
Drugs, 2012 Jun 13; 72(9). PMID: 22686613
Review.
A CXCL1 paracrine network links cancer chemoresistance and metastasis.
Swarnali Acharyya, Thordur Oskarsson, +10 authors, Joan Massagué.
Cell, 2012 Jul 10; 150(1). PMID: 22770218    Free PMC article.
Highly Cited.
CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Zeyana Rivera, Soldano Ferrone, +6 authors, Michele Carbone.
Clin Cancer Res, 2012 Aug 16; 18(19). PMID: 22893632    Free PMC article.
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
Zahi Mitri, Tina Constantine, Ruth O'Regan.
Chemother Res Pract, 2013 Jan 16; 2012. PMID: 23320171    Free PMC article.
Highly Cited.
Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer.
Dong Hui Cho, Se Kyung Lee, +12 authors, Jung-Hyun Yang.
J Korean Surg Soc, 2013 May 07; 84(5). PMID: 23646312    Free PMC article.
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Maike Ihnen, Christine zu Eulenburg, +18 authors, Gottfried E Konecny.
Mol Cancer Ther, 2013 Jun 05; 12(6). PMID: 23729402    Free PMC article.
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Teddy S Nagaria, Julia L Williams, +3 authors, Waheed Sangrar.
Neoplasia, 2013 Aug 03; 15(8). PMID: 23908594    Free PMC article.
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Filippo Montemurro, Aleix Prat, +9 authors, Maurizio Scaltriti.
Mol Oncol, 2013 Oct 01; 8(1). PMID: 24075779    Free PMC article.
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.
Jingcao Huang, Shuiliang Wang, +4 authors, Bolin Liu.
Mol Cancer, 2013 Nov 13; 12(1). PMID: 24215614    Free PMC article.
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Pedro J Beltran, Frank J Calzone, +11 authors, Gottfried E Konecny.
Clin Cancer Res, 2014 Apr 15; 20(11). PMID: 24727326    Free PMC article.
Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer.
L Alexis Hoeferlin, Charles E Chalfant, Margaret A Park.
J Surg Sci, 2014 May 13; 1(1). PMID: 24818173    Free PMC article.
Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-positive or high-risk node-negative breast cancer.
Sara A Hurvitz, Linda D Bosserman, +6 authors, Dennis J Slamon.
Springerplus, 2014 May 27; 3. PMID: 24860718    Free PMC article.
Presentation and management of docetaxel-related adverse effects in patients with breast cancer.
Maria Y Ho, John R Mackey.
Cancer Manag Res, 2014 Jun 07; 6. PMID: 24904223    Free PMC article.
Review.
Trastuzumab-conjugated liposome-coated fluorescent magnetic nanoparticles to target breast cancer.
Mijung Jang, Young Il Yoon, +5 authors, Sun Mi Kim.
Korean J Radiol, 2014 Jul 24; 15(4). PMID: 25053899    Free PMC article.
Evaluation of (89)Zr-pertuzumab in Breast cancer xenografts.
Bernadette V Marquez, Oluwatayo F Ikotun, +4 authors, Suzanne E Lapi.
Mol Pharm, 2014 Jul 25; 11(11). PMID: 25058168    Free PMC article.
Gastric cancer: toward a cisplatin-free disease?
Fausto Petrelli, Sandro Barni, Stefano Cascinu, Alberto Zaniboni.
J Gastrointest Oncol, 2014 Aug 02; 5(4). PMID: 25083304    Free PMC article.
Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.
Josep Lluís Parra-Palau, Beatriz Morancho, +14 authors, Joaquín Arribas.
J Natl Cancer Inst, 2014 Sep 26; 106(11). PMID: 25253614    Free PMC article.
Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer.
Ciara C O'Sullivan, Karen L Smith.
Curr Breast Cancer Rep, 2014 Oct 07; 6(3). PMID: 25285186    Free PMC article.
The trastuzumab and vinorelbine combination: an alternative to taxane-based chemotherapy for early-stage and locally advanced her2-positive breast cancer.
K Esfahani, C Ferrario, P Le, L Panasci.
Curr Oncol, 2014 Oct 11; 21(5). PMID: 25301539    Free PMC article.
Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins.
Yongping Liu, Yang Ling, +4 authors, Changsong Zhang.
Oncol Lett, 2015 Jan 28; 9(2). PMID: 25624920    Free PMC article.
The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.
Takashi Ishikawa, Takeshi Sasaki, +12 authors, Itaru Endo.
J Surg Sci, 2015 Feb 03; 2(1). PMID: 25642443    Free PMC article.
Assessing the role of platinum agents in aggressive breast cancers.
William M Sikov.
Curr Oncol Rep, 2015 Feb 11; 17(2). PMID: 25665554
Review.
Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition.
Aaron Goldman, Biswanath Majumder, +5 authors, Shiladitya Sengupta.
Nat Commun, 2015 Feb 12; 6. PMID: 25669750    Free PMC article.
Highly Cited.
The role of HER-2 in Breast Cancer.
Takashi Ishikawa, Yasushi Ichikawa, +5 authors, Itaru Endo.
J Surg Sci, 2015 Feb 14; 2(1). PMID: 25679012    Free PMC article.
A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.
Qi Zhao, Hoa Tran, Dimiter S Dimitrov, Nai-Kong V Cheung.
Int J Cancer, 2015 May 01; 137(9). PMID: 25924852    Free PMC article.
Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer.
Masako Kanematsu, Manabu Futamura, +7 authors, Kazuhiro Yoshida.
Cancer Med, 2015 Jun 17; 4(9). PMID: 26077887    Free PMC article.
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Carlo Palmieri, Iain Rj Macpherson, +14 authors, Sacha J Howell.
Oncotarget, 2015 Sep 04; 7(11). PMID: 26334099    Free PMC article.
The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.
Diogo Mendes, Carlos Alves, +5 authors, Francisco Batel-Marques.
Breast Cancer Res, 2015 Nov 19; 17. PMID: 26578067    Free PMC article.
Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Martina Di Modica, Lucia Sfondrini, +8 authors, Elda Tagliabue.
Oncotarget, 2015 Nov 26; 7(1). PMID: 26595802    Free PMC article.
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Didier Meulendijks, Laurens V Beerepoot, +15 authors, Annemieke Cats.
Invest New Drugs, 2015 Dec 09; 34(1). PMID: 26643663
Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial.
Christiane Thallinger, Istvan Lang, +7 authors, Christoph Zielinski.
BMC Cancer, 2016 Feb 19; 16. PMID: 26887956    Free PMC article.
Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer.
Jing Xiong, Tiefen Su, +4 authors, Sheng Zhou.
Oncotarget, 2016 Mar 24; 7(17). PMID: 27004407    Free PMC article.
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Laura Pizzuti, Maddalena Barba, +18 authors, Patrizia Vici.
J Cell Physiol, 2016 May 18; 231(11). PMID: 27187274    Free PMC article.
Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
Edith A Perez, José Manuel López-Vega, +5 authors, Michael Andersson.
Breast Cancer Res, 2016 Dec 14; 18(1). PMID: 27955684    Free PMC article.
Tuning polypeptide-based micellar carrier for efficient combination therapy of ErbB2-positive breast cancer.
Kruti S Soni, Fan Lei, +3 authors, Tatiana K Bronich.
J Control Release, 2017 Sep 06; 264. PMID: 28870832    Free PMC article.
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
Nalo Hamilton, David Austin, +6 authors, Richard Pietras.
Int J Mol Sci, 2017 Nov 04; 18(11). PMID: 29099049    Free PMC article.
Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems.
Teddy S Nagaria, Changnian Shi, +4 authors, Peter A Greer.
Oncotarget, 2017 Nov 09; 8(46). PMID: 29113345    Free PMC article.
Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Heikki Joensuu, Judith Fraser, +20 authors, Henrik Lindman.
JAMA Oncol, 2018 Jun 01; 4(9). PMID: 29852043    Free PMC article.
Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells.
Sandeep Palvai, Libi Anandi, +4 authors, Sudipta Basu.
ACS Omega, 2018 Jul 20; 2(12). PMID: 30023590    Free PMC article.
Clinical Significance of Elevated S100A8 Expression in Breast Cancer Patients.
Dujuan Wang, Guohong Liu, +3 authors, Yunbao Pan.
Front Oncol, 2018 Nov 21; 8. PMID: 30456203    Free PMC article.
Targeting tumor cells with antibodies enhances anti-tumor immunity.
Zhichen Sun, Yang-Xin Fu, Hua Peng.
Biophys Rep, 2018 Dec 12; 4(5). PMID: 30533489    Free PMC article.
Molecular Mechanisms of Antitumor Activity of PAMAM Dendrimer Conjugates with Anticancer Drugs and a Monoclonal Antibody.
Monika Marcinkowska, Maciej Stanczyk, +4 authors, Barbara Klajnert-Maculewicz.
Polymers (Basel), 2019 Sep 01; 11(9). PMID: 31470686    Free PMC article.
Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Yoseop Kim, Soo-Hyeon Lee, +5 authors, Sang-Ki Kim.
BMC Vet Res, 2019 Oct 16; 15(1). PMID: 31610784    Free PMC article.
Functional and Nonclinical Similarity of ABP 980, a Biosimilar of Trastuzumab.
Shea Jassem, Wei Wang, +9 authors, Helen J McBride.
Pharm Res, 2019 Nov 07; 36(12). PMID: 31696314    Free PMC article.
Experimentally-driven mathematical modeling to improve combination targeted and cytotoxic therapy for HER2+ breast cancer.
Angela M Jarrett, Alay Shah, +4 authors, Anna G Sorace.
Sci Rep, 2019 Sep 08; 9(1). PMID: 31492947    Free PMC article.
Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Giuseppe Gullo, Naomi Walsh, +15 authors, John Crown.
Br J Cancer, 2018 May 19; 119(3). PMID: 29773838    Free PMC article.
Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.
Diana C Márquez-Garbán, Manuel Gorrín-Rivas, +4 authors, Richard J Pietras.
Cancer Lett, 2019 Feb 17; 449. PMID: 30771431    Free PMC article.
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.
G Brockhoff, B Heckel, +4 authors, S Diermeier.
Cell Prolif, 2007 Jul 20; 40(4). PMID: 17635517    Free PMC article.
Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models.
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, +2 authors, Ala-Eddin Al Moustafa.
Cancers (Basel), 2020 Mar 14; 12(3). PMID: 32164163    Free PMC article.
Review.
Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines.
Richard Schroeder, Mary Sfondouris, +6 authors, Jayalakshmi Sridhar.
ACS Omega, 2019 Aug 29; 4(6). PMID: 31460159    Free PMC article.
Trastuzumab-containing regimens for metastatic breast cancer.
Sara Balduzzi, Stefania Mantarro, +4 authors, Roberto D'Amico.
Cochrane Database Syst Rev, 2014 Jun 13; (6). PMID: 24919460    Free PMC article.
Systematic Review.
Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
Richard L Schroeder, Cheryl L Stevens, Jayalakshmi Sridhar.
Molecules, 2014 Sep 25; 19(9). PMID: 25251190    Free PMC article.
Review.
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Cristina Nieto-Jimenez, Ana Alcaraz-Sanabria, +7 authors, Alberto Ocaña.
Int J Mol Sci, 2020 Dec 03; 21(23). PMID: 33261142    Free PMC article.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Toshinari Yamashita, Hidetoshi Kawaguchi, +16 authors, Masakazu Toi.
Invest New Drugs, 2020 Aug 25; 39(1). PMID: 32833136    Free PMC article.
Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer.
Andrea Rocca, Pietro Cortesi, +18 authors, Anna Fedeli.
Ther Adv Med Oncol, 2021 Feb 23; 13. PMID: 33613693    Free PMC article.
Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
Zijing Wang, Jiaxuan Liu, +8 authors, Binghe Xu.
Breast Cancer Res Treat, 2021 Apr 26; 188(2). PMID: 33895900    Free PMC article.
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Early Breast Cancer Trialists’ Collaborative group (EBCTCG).
Lancet Oncol, 2021 Aug 03; 22(8). PMID: 34339645    Free PMC article.
Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy.
Agnieszka Gornowicz, Wojciech Szymanowski, +2 authors, Anna Bielawska.
PLoS One, 2021 Aug 27; 16(8). PMID: 34437575    Free PMC article.
A careful reassessment of anthracycline use in curable breast cancer.
Sara Alsterlind Hurvitz, Nicholas P McAndrew, +8 authors, Dennis J Slamon.
NPJ Breast Cancer, 2021 Oct 10; 7(1). PMID: 34625570    Free PMC article.
Review.